CTRI/2022/07/044004尚未招募未知
A preliminary study to validate BM-AspICU algorithm for diagnosing invasive pulmonary aspergillosis in critically ill mechanically ventilated patients using post-mortem minimally invasive tissue sampling
ICMR0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Patient intubated and mechanically ventilated for >= 48 hours
- •2. The patient has one of the following: A or B or C
- •A . Clinical features
- •1)Fever refractory to > 3 days of antibiotics
- •2)Pleuritic chest pain
- •4)Hemoptysis
- •5)Respiratory insufficiency despite ventilation support
- •B. Imaging sign
- •HRCT thorax or Chest radiography suggestive of >= 1 features
- •1)Air-crescent sign
- •3)Dense, well-circumscribed lesion(s) with or without halo sign
- •4)Diffuse reticular and alveolar opacities
- •5)Nonspecific infiltrates and consolidation
- •6)Pleural fluid
- •7)Wedge-shaped infiltrate
- •8)Tree-in-bud pattern
- •C. Positive Aspergillus culture in the lower respiratory tract
- •3. Post-mortem histopathological samples from lungs obtained
排除标准
- •1.Patient or attendants not giving consent for participating in the study
- •2.Patients whose fungal biomarkers and other investigation reports are not available
- •3. Patients intubated and mechanically ventilated for < 48 hours
研究者
相似试验
已完成
1 期
To assess the efficacy of a new device (RC device) in patients requiring ventilation in emergency departmentCTRI/2020/09/027819Rajeev Chauhan10
进行中（未招募）
不适用
A phase II study to determine the activity of BMS-354825 in subjects with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia who have disease that is resistant to high dose imatinib mesylate (Gleevec) or who are intolerant of imatinibChronic myeloid leukemiaMedDRA version: 6.1Level: HLTClassification code 10024296EUCTR2004-002601-69-ITBRISTOL-M.SQUIBB240
已完成
不适用
A phase I, open-label study to investigate the absorption, metabolism, excretion, and mass balance of [14C]QLT091001 following single oral dose in healthy male subjectsNL-OMON35776QLT Inc.6
进行中（未招募）
不适用
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with ChronicPhase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who HaveDisease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who areIntolerant of ImatinibRevised Protocol 01 version 4.0, incorporating Amendment 02 and Administrative Letter dated 01-Mar-2005, and Amendment 01 version 2.0 dated 28-Apr-2005Chronic phase Philadelphia chromosome-positive chronic myeloid leukemiaEUCTR2004-002601-69-DKBristol Myers Squibb International Corporation250
进行中（未招募）
不适用
A Phase II Study to Determine the Activity of BMS-354825 in Subjects with ChronicPhase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who HaveDisease that is Resistant to High Dose Imatinib Mesylate (Gleevec) or Who areIntolerant of ImatinibRevised Protocol 01 version 4.0, incorporating Amendment 02 and Administrative Letter dated 01-Mar-2005, and Amendment 01 version 2.0 dated 28-Apr-2005EUCTR2004-002601-69-DEBristol Myers Squibb International Corporation250